Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Capivasertib + Enzalutamide
Indication/Tumor Type prostate cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable Capivasertib + Enzalutamide Phase I Actionable In a Phase I trial, Capivasertib (AZD5363) and Xtandi (enzalutamide) combination treatment was well-tolerated and demonstrated safety, and resulted in an overall response rate of 25% (3/12) in evaluable metastatic castration-resistant prostate cancer patients (n=16) harboring either a PTEN loss or AKT1 E17K (PMID: 32205016; NCT02525068). 32205016
PubMed Id Reference Title Details
(32205016) A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Full reference...